Modifying Virtual Reality Analgesia With Low-Dose Pain Medication

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01840774

Enrollment

Registered

2013-04-26

Start date

2013-04-30

Completion date

2014-06-30

Last updated

2013-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Virtual Reality Therapy

Brief summary

The purpose of this study is to determine how pain relief is modified when the investigators combine the Virtual Reality based Snow World game with certain pain medications.

Detailed description

This is a randomized, double-blind, placebo-controlled, within subject 2x2 factorial, repeated measures study. Research participants will play two versions of the Virtual Reality based video game Snow World and be given thermal and electrical stimulus. Each of two study visits will be identical with the exception of whether or not the participant will receive an iv infusion of a low dose pain medication or a saline placebo.

Interventions

DRUGLow-dose pain medication (Ketalar) and saline placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male and females between the age of 18 and 60 years * Ability to communicate orally * Ability to read and understand English * Body Mass Index between 20-35

Exclusion criteria

* Women who are pregnant, trying to become pregnant, or who are breastfeeding * History of alcohol or substance abuse * Major medical illness; including history of migraine headaches, seizures, brain injury, or peripheral neuropathy * Current use of analgesics including acetaminophen, non-steroidal anti-inflammatories, or opioids * Predisposition to severe motion sickness * Unusual sensitivity or lack of sensitivity to pain * Urine toxicology positive for opioids or benzodiazepines

Design outcomes

Primary

Measure	Time frame
Pain responses between placebo and the low-dose pain medication while playing Snow World. We will assess pain responses with subjective questionnaires concerning the participant's experience while playing Snow World.	Conclusion of 120 study visits. Each participant will spend a total of 8 hours with us.

Countries

United States

Contacts

Primary ContactChristine Hoffer, BA

hoffer@uw.edu206-616-3075

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026